The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery.
William Sohn
No relevant relationships to disclose
Alan Paciorek
No relevant relationships to disclose
Peter Carroll
Consultant or Advisory Role - Abbott Laboratories (U); Abbott Laboratories (U); AstraZeneca; AstraZeneca; Department of Defense (U); Genome Dx; GenomeDx Biosciences ; Genomic Health (U); Genomic Health (U); Myriad Genetics (U); Myriad Genetics (U); NCI (U)
David F. Penson
No relevant relationships to disclose
Atreya Dash
No relevant relationships to disclose